Results 111 to 120 of about 39,011 (251)
The protein science of biosimilars [PDF]
, 2006 Martin K. Kuhlmann, Adrian Covic
openalex +1 more source
Regulatory Science Ireland: bridging the information gap on biosimilar medicines [PDF]
, 2016 Regulatory Science Ireland (RSI) is a voluntary network of interested parties from academia, the Health Products Regulatory Authority (HPRA), pharmaceutical and medical device industries and government agencies.
Barry, Sean P. +6 more
core +1 more source
Biosimilar medicines uptake: The role of the clinical pharmacist
Exploratory Research in Clinical and Social Pharmacy, 2021 The introduction of biological medicines has revolutionized the management of chronic diseases. Due to the high cost of biological medicine coupled with the fact that patents of many of these medicines are on the verge of expiration, manufacturers are ...
Roland Nnaemeka Okoro
doaj
Biosimilar biological drugs in the treatment of inflammatory bowel diseases
Gastroenterology Review, 2019 Within the last 20 years, tumour necrosis factor inhibitors have been proven to be effective in achieving and maintaining clinical and endoscopic remission in patients with Crohn’s disease and ulcerative colitis.
Magdalena Kaniewska +6 more
doaj +1 more source
Monoclonal antibody biosimilars for cancer treatment
iScienceSummary: Monoclonal antibodies are important cancer medicines. The European Medicines Agency (EMA) approved 48 and the Food and Drug Administration (FDA) 56 anticancer monoclonal antibody-based therapies.
Linda N. Broer +6 more
doaj
Non‐Clinical Safety Studies on Biosimilar Recombinant Human Erythropoietin [PDF]
, 2007 Michael J. Parnham +2 more
openalex +1 more source
Understanding the market dynamics of biosimilars
, 2016 Biosimilars represent an attractive market opportunity in the pharmaceutical industry. In order to understand the underlying market dynamics and to identify the success factors of the biosimilars market, a PEST (political, economic, social, technological)
Dassow, J. (Jonas) +3 more
core
Biosimilars and biopharmaceuticals: what the nephrologist needs to know--a position paper by the ERA-EDTA Council [PDF]
, 2009 Stanley Shaldon
openalex +1 more source